You mean compliment, correct?
Not like complement, meaning along the same, such as lines, flooring joists, etc.
Correct, outsourced consultant.
He could speak for Oncosec but surely due to non-disclosure agreements and NDA's attached to his academia career, he can only speak so much to ensure no conflict of interest.
As I stated above, still a good sign of things to come in the future.
He's basically a consultant from what I gathered with he article.
Sure he might wear an Oncosec shirt on occasion but he's still majority focused on his academia career. Maybe in due time Oncosec, but that time is not today.
Still a positive sign as he is well-known is his field.
I simply don't want people to get the wrong impression that he simply jumped ship to work for Oncosec and left academia entirely. For clarification purposes, this is not the case.
Good consultant addition nonetheless.
Where did you read that he's a direct employee? I read no such thing in the article that he was leaving his academia world for the corporate world. Please verify your findings Sal.
I'm not sure he's 100% leaving UCSF, but rather being added as chief clinical consultant.
Article did not clarify if he's leaving academia for corporate world. My guess would be no.
Either way, it's positive news.
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, has named Adil Daud, M.D. as Chief Clinical Strategist.
Dr. Daud is a longstanding member of OncoSec’s Melanoma Advisory Board and serves as Principal Investigator for OncoSec’s Phase 2 melanoma study. He is a clinical professor of hematology/oncology at University of California, San Francisco (UCSF), and Director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Daud is a nationally recognized expert in early-phase drug development in skin cancer and solid tumors, and has co-authored more than 60 scientific publications. Prior to joining UCSF in 2008, Dr. Daud served at Memorial Sloan-Kettering Cancer Center in New York and H. Lee Moffitt Cancer Center in Florida. He has been the recipient of numerous awards, including the American Society for Clinical Oncology’s Young Investigator award and Castle Connolly’s Best Doctors in America award.
Dr. Daud said, “I am both honored and excited to take on this expanded role as Chief Clinical Strategist for OncoSec Medical. I believe this is a watershed moment in oncology, and that intralesional therapies like those being advanced by the OncoSec team have the potential to provide serious benefit to many patients around the globe.”
“Dr. Daud is a pioneer in the field of gene-electro therapy,” said Punit Dhillon, President and CEO. “His Phase I study investigating the use of in-vivo electroporation to deliver plasmid DNA laid the groundwork for OncoSec’s formation, and his efforts have proved integral to the company’s development. Adil’s work continues to support his status as a key opinion leader in intralesional immunotherapies.”
As Chief Clinical Strategist, Dr. Daud will take on an expanded clinical leadership role. Among his central duties will be to advise on protocol and development, liaise with key stakeholders and represent the company at conferences.
Exactly, buy the rumor, sell the news has been in effect nearly 24-30/months already.
It's not just ONCS but the entire market is general.
Gone are the days of buy the news, sell the rumor.
Brother, I tend to consider you a resident permabull (never a bad thing to say), but your insight, foresight and knowledge is undisputed. I honestly really like reading your messages on this board. Excellent job brother.
I entrust you will do well looking for information regarding missing kids. Best of luck with the new position.
Not exactly an argument. I suppose I was learning towards this...
Let'e say we so through a few successful trials and eventually get approved in due time.
Who's liable to the guy that's 66 year old going into elctroporation treatment for the first time, and boom, the patient simply drops dead (his fault because he didn't indicate in the checkbox that he's experiencing minor heart pains, chest pain, etc). People are stubborn, unless this 66 year old man had a documented surgery, he might not even disclose his minor chest pain.
If he drops dead, who's liable? We surely are of course.
For the folks that answer we would not be liable due to disclaimers, his signature on papers, warning label on the machine or anything else, you're dead wrong here.
I know from experience all that stuff is simply noise as a precaution. My father passed away from mesothelioma and rest assured we took plenty of action against 65+ companies. We're about 50-0 thus far with about 15/lawsuits to go. We haven't lost a product liability or wrongful death lawsuit yet, despite all those California cancer warning labels on the back of products.
Agree with your theory on the smooth sailing ahead, which is typically good for biotech stocks.
I'm simply stating the facts from my own experience in the medical field. The wife is also in the field at the university level, etc.
I'm not the most knowledgeable on the board regarding the medical/cancer research industry, but at the same token, I'm surely not the most uninformed either.
I think it's mildly related my friend.
I just wouldn't want this to march through a successful P2, P3 and eventful approval to simply have it labeled as limited use for older patients that have a history or cardiac/heart trouble, pacemarker folks or have had previous heart attacks.
As many of us know, cancer typically occurs in elder patients (Melanoma too). Many elder patients have heart-related trouble (and that's only increasing due to the uber rise in the obesity rate). Leaving this subgroup behind as potential treatment candidates is simply leaving a penultimate business on the table for someone else's taking.
Clearly ONCS is making advancements here.
One of my main concerns of the few I posted was the concern regarding the pain, albeit brief of the electroporation electrical shock.
Apparently ONCS is addressing this issue by the new hire addition:
Dr. Campbell, an Associate Professor in the Department of Pathology in the School of Medicine at the University of Washington, Seattle, will leverage her considerable expertise in cancer biology and signal transduction to investigate mechanisms of immune tolerance in cancer.
Keyword - TOLERANCE
Stars continue to be aligning.
One of my 4-5 negatives that I posted to FURBUSH/BROTHER/ETC has seem to be subsiding as ONCS appears be be addressing the treatment tolerance factor. No complaints whatsoever.
Punit's a finance guy, rest assured he will not offer shares in times of turbulent seeing he just made a 40k dollar purchase a few weeks prior.
Rest assured he'll complete an offering when the markets are once again soaring into the year end (sept-dec) range when it's not even relevant because ONCS will be $1.50-$2.50 by then are issuing shares at that price will be welcome to shore up financials for future uplisting to NASD.
Rest assured, a savvy finance guy at the helm knows how to play his cards right.
Just my humble opinion of course. Overall I agree with Furbush's sentiment of Q4.